Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2Phase 3 Interventional

A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures

ClinicalTrials.gov ID: NCT00387686

Public ClinicalTrials.gov record NCT00387686. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study Of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) In Closed Diaphyseal Tibial Fracture

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to assess whether a single dose of rhBMP-2/CPM administered at the fracture site via percutaneous injection, in combination with standard of care, accelerates fracture union and return to normal function in subjects who have a closed diaphyseal tibial fracture when compared to standard of care alone.

Study identification

NCT ID
NCT00387686
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2, Phase 3
Enrollment
367 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2006 (Type not available)
Primary completion
Jul 2009 (Actual)
Completion
Mar 2010 (Actual)
Last update posted
Feb 28, 2013

2006 – 2010

United States locations

U.S. sites
17
U.S. states
12
U.S. cities
16
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35294-3708 —
Pfizer Investigational Site Birmingham Alabama 35294 —
Pfizer Investigational Site Aurora Colorado 80012 —
Pfizer Investigational Site Denver Colorado 80204 —
Pfizer Investigational Site New Haven Connecticut 06519 —
Pfizer Investigational Site Pinellas Park Florida 33781 —
Pfizer Investigational Site Fort Wayne Indiana 46804 —
Pfizer Investigational Site Indianapolis Indiana 46202 —
Pfizer Investigational Site Baltimore Maryland 21201-1595 —
Pfizer Investigational Site Kalamazoo Michigan 49007 —
Pfizer Investigational Site Portage Michigan 49002 —
Pfizer Investigational Site Lebanon New Hampshire 03756 —
Pfizer Investigational Site New Brunswick New Jersey 08901 —
Pfizer Investigational Site Brooklyn New York 11220 —
Pfizer Investigational Site Elmhurst New York 11373 —
Pfizer Investigational Site Charlotte North Carolina 28203-5871 —
Pfizer Investigational Site Memphis Tennessee 38103 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00387686, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 28, 2013 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00387686 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →